purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation bcrx earnings call period ending march image source motley fool biocryst pharmaceutical bcrx q earnings callmay etcontents prepared remark question answer call participant prepared remark operatorgood morning welcome biocryst first quarter earnings call operator instruction please note event recorded would like turn conference john bluth biocryst please go aheadjohn bluth senior vice president investor relation corporate communication thanks drew good morning welcome biocryst first quarter corporate update financial result conference call today press release accompanying slide available website participating today ceo jon stonehouse cfo anthony doyle chief commercial officer charlie gayer chief rd officer dr helen thackray following remark answer question begin please note today conference call contain forwardlooking statement including statement regarding future result unaudited forwardlooking financial information well company future performance andor achievement statement subject known unknown risk uncertainty may cause actual result performance achievement materially different future result performance expressed implied presentationyou place undue reliance forwardlooking statement additional information including detailed discussion risk factor please refer company document filed security exchange commission accessed website addition today conference call includes nongaap pro forma financial measure reconciliation nongaap measure directly comparable gaap financial measure please refer earnings press release posted press release section investor relation website wwwbiocrystcom would like turn call jon stonehouse jon stonehouse chief executive officer thanks john fantastic start year growing orladeyo revenue pipeline advancing schedule orladeyo revenue q exceeded expectation commercial team yous great job successfully navigating reauthorization process faster previous year charlie share detail fourth year since approval steady consistent growth new patient show sign letting even confident track reach goal billion global revenue peak continue make great progress prioritized pipeline orladeyo pediatric program schedule file approval next year continue make progress bcx expect able decide whether partner discontinue program later year addition pipeline program including bcx netherton avoralstat dme advancing toward clinic first bestinclass profile next month orladeyo approaching midway point global peak revenue goal preparing file approval orladeyo use pediatric patient starting move multiple pipeline program patient study last least approaching profitability year strong start exceptional progress area focused continuing momentum throughout year turn charlie share outstanding performance orladeyo quartercharlie gayer chief commercial officer thanks jon quarter continued execute global plan orladeyo effectively revenue million exceeded expectation efficient handling prescription reauthorizations united state combined continued strong demand healthcare provider gain confidence orladeyo based improvement trend raising orladeyo revenue guidance top half prior range forecast million million year describe improvement trend specifically last year invested patient service market access team goal improving efficiency effectiveness patient paid therapy first quarter show investment working two fact stand improvement first patient service team completed benefit investigation january entire first quarter resulting patient getting back paid therapy quicker previous year completing investigation early first quarter give better understanding ease difficulty reauthorization process easy get paid shipment quickly going difficult team act faster better information solve issue second even though still provided temporary free product many patient first quarter reauthorizations faster action quarter meant paid shipment within fourth quarter paid shipment expectation customer demand another strong quarter new patient prescription fact last two quarter best consecutive quarter demand since six month launch patient healthcare provider continued understand gain confidence get great efficacy convenience orladeyo one capsule day prevent hae attack also continued strengthen brand presenting new evidence showing realworld impact orladeyo quad ai february showed well orladeyo controlling hae attack regardless prior therapy baseline attack rate patient switching orladeyo prophylaxis therapy example maintain even improve longterm attack control reaching median rate half attack per month patient attack free baseline remained attack free orladeyo later week present new data ispor conference atlanta demonstrating patient initiating orladeyo experienced significant reduction overall healthcare resource utilization finding meaningful payer wellpositioned provide frequent health economics health outcome economics update large growing cohort already include hundred patient new data support growth customer demand orladeyo many year come increasing customer confidence seeing yous also happening rest world patient growth europe strong consistent first quarter recent launch spain italy already adding trend finally biocryst japan team fully place start encouraged early sign impact overall trend realworld evidence customer confidence patient growth continue point million peak yous revenue sustained peak global revenue billion hand helen provide update pipelinehelen thackray chief research development officer thanks charlie research development team busier ever rapidly approaching next major pipeline milestone include advancing multiple program clinic starting later year filing pediatric approval orladeyo let u start pleased share completed enrollment pediatric trial orladeyo includes extending dosing child two year age mean track submit pediatric registration planned also mean even closer providing first oral prophylactic therapy child hae remarkable quickly pediatrics enrolled believe reflects demand oral therapy prophylaxis hae attack child potential transformative option child parent pediatric formulation made granule sprinkled soft food taken glass water excited close achieving goal bringing orladeyo child look forward submitting registration next year turning next clinical program factor inhibitor bcx continue progress ongoing proof concept trial expect either partner discontinue program later year planned next two pipeline program enter clinic within month bcx netherton syndrome avoralstat diabetic macular edema dme track begin clinical trial bcx end year fusion protein high potency inhibition klk potential bestinclass product providing diseasealtering treatment people netherton syndrome netherton syndrome rare lifelong genetic disorder often present infancy red scaly inflamed skin patient require chronic care protect skin monitor lifelong susceptibility inflammatory atopic condition netherton syndrome life threatening especially infancy neonate vulnerable dehydration recurrent infection currently approved treatment netherton syndrome goal deliver targeted therapy patient next clinic avoralstat plasma kallikrein inhibitor development treatment diabetic macular edema dme track initiate trial patient next year goal improve vision patient persistent dme despite use vegf inhibitor least third patient dme continuing symptom even worsening vision loss treated vegf inhibitor may plasma kallikrein contributing disease need additional therapeutic option real working clearside deliver avoralstat suprachoroidal space eye order achieve sufficient exposure right location interrupt pathophysiology dme retina stop swelling back eye based preclinical safety data accumulated avoralstat studied hae program position move quickly patient dme first clinical trial next year evaluate proof concept directly patient right behind two program discovery program target across complement system also advancing three program underway include protein therapeutic complement inhibitor targeting three pathway classical lectin alternative pathway complement oral c oral c inhibitor small molecule track oral c inhibitor protein therapeutic multifunctional complement inhibitor advance indenabling study later year summary continue progress well toward goal delivering inhibitor every pathway complement system overall depth breadth pipeline provides balance great potential diversified set molecule moving forward allows u increase likelihood pipeline today produce next drug market tomorrow excited pipeline advancing clinic multiple program next turn anthony financial updateanthony doyle chief financial officer thanks helen find detailed first quarter financials today earnings press release would like call attention item total revenue quarter million million came orladeyo remaining million coming rapivab sale put orladeyo trailing month revenue million q revenue increasing q million global orladeyo revenue sale million came yous sale remaining million coming ex sale yearoveryear increase sale primarily driven strong underlying patient growth continued see quarter quarter million improvement q performance versus previous guidance million primarily driven effort commercial team improve accelerate reauthorization process million last year would able capture q year team managed accelerate timing achieve quarter one q expect achieve revenue approximately million charlie said revised full year revenue guidance higher end range million million operating expense including noncash stock compensation quarter million increase million q included million onetime expense related rd structuring beginning year fullyear guidance opex unchanged million million revenue million year year million opex million year year million continue see improved margin accretion operating loss quarter including noncash stock comp le million cash end quarter million net cash utilization quarter million q historically largest quarter year cash utilization context last year q responsible total cash utilization entire year including q year million related rd restructuring million related royalty payment omers first quarter making cash payment omers reminder royalty considered debt instrument gaap purpose called ultimately considered longterm liability true debt additionally revised guidance fullyear orladeyo revenue result improved blended royalty rate revenue fall million tier royalty reduced rate cash utilization decline remaining quarter year last year closer average million million per quarter expect end year million cash great see continuing strong performance orladeyo commercial team outstanding job improve performance reauthorization process improvement would hope continue build upon next year quarter strengthened revenue performance supported continued strong underlying patient demand drive revised fullyear revenue guidance million million fullyear opex remaining consistent guidance even stronger position deliver operating profit year excluding noncash stock comp continue planned path nearterm profitability shared earlier year approaching quarterly cash flow eps positivity late next year full year cash flow eps positivity continuing advance pipeline full pace without need raise additional capital get operator open question question answer operatoroperator instruction first question come jessica fye jp morgan please go aheadunknown speaker hey nick jess congrats quarter thanks taking question two u mentioned past two quarter new prescription yous since first two quarter launch maybe provide additional detail trend looking far q maybe one ex yous revenue know came q talked lumpier lumpier yous expect growth expect growth ex yous business year point could become le lumpyjon stonehouse chief executive officer charlie take first one anthony take second onecharlie gayer chief commercial officer sure going comment yet q two consecutive quarter really great prescription talked talked market research physician continue expect grow orladeyo prescription next year would expect kind demand continuejon stonehouse chief executive officer hey charlie worth spending little bit time talking confidence seeing physician patient stage since approvalcharlie gayer chief commercial officer sure yeah like said prepared remark physician gained experience patient well see drug much convenient oral therapy see orladeyo really effective therapy know expect high efficacy convenience together give confidence prescribing physician know majority patient would prefer oral therapy get really effective oral therapy make want prescribe think seeing threeplus year launchjon stonehouse chief executive officer nick confidence see letting anthonyanthony doyle chief financial officer yeah exyous yes nature sell ex yous market always going lumpiness last year total revenue come ex yous would expect something similar year mean due yous overperformance opposed ex yous expect ultimately would expect ex yous sale continue increase year year get peakcharlie gayer chief commercial officer add lumpiness really based distribute nothing customer demand seeing physician gaining kind confidence described yous expect continueunknown speaker great thank youoperatorthe next question come maury raycroft jefferies please go aheadmaury raycroft jefferies analyst hi congrats quarter thanks taking question prepared remark talked patient service team investigation early first quarter led categorizing reauthorizations easy versus difficult talk make reauthorizations easy versus difficult plan building upon learning rest year thatcharlie gayer chief commercial officer sure maury kind rare disease therapy payer always trying make thing little bit difficult kind thing described want full patient history want lab test want information get sometimes payer already information make pretty quick get reauthorization kind payer interest throw many speed bump possible even provided sometimes ask provided patient complicated history bigger challenge team great success getting type patient approved sometimes quick sometimes take little bit time everything see though give confidence paid rate peak going take u year get therejon stonehouse chief executive officer think piece charlie made decision little year ago change model improve reimbursement support service around starting see fruit think continue see year progress future year great great signal great signalmaury raycroft jefferies analyst got maybe quick question comment way say seeing gross net price increase took january something expect going forward next couple yearsjon stonehouse chief executive officer first one take secondanthony doyle chief financial officer yeah gtn side reimbursed product historically much like last year q higher end range closer remainder year based speed charlies team got reauth process would expect come lower endcharlie gayer chief commercial officer maury year beginning year price increase expect net far growth million peak yous would expect modest price increase part build toward millionmaury raycroft jefferies analyst got thanks taking questionsoperatorthe next question come tazeen ahmad bank america please go aheadtazeen ahmad bank america merrill lynch analyst hi guy good morning thanks taking question ask color expect make final decision asset going presenting data intend move forward wanted ask question guidance based still early year possible could revise upper end guidance higher year progress based trend seeing farjon stonehouse chief executive officer yeah said beginning year goal either partner stop program next thing likely hear whether decided partner drug guidance adjusted bottom range confident adjust let know right moving bottom upoperatorok followup questiontazeen ahmad bank america merrill lynch analyst think answered thanksoperatorthank next question come serge belanger needham companyserge belanger needham company analyst good morning thanks taking question nice orladeyo quarter guess charlie mentioned two strong quarter patient growth exceeding first two quarter launch give u little color maybe compare yearoveryear basis success reauthorization process sound like going see usual seasonality trend curious think longterm target paid script still target move timeline hit target thankscharlie gayer chief commercial officer thanks serge clarify one thing last two quarter best two quarter since first two quarter launch first two quarter slightly better think show bolus patient early got demand fall demand actually building time customer gain confidence like saying one previous response growth revenue year year think kind speaks point launch growing strongly impressive far q seasonality anthony saying would expect big jump year guiding million q would expect kind trend think future going get revenue first quarter effective reauthorization process far growth underlying improvement rate paid commented going take u year get improvement making adding team getting better better year going process tell going get bigger jump bigger opportunity would next year ira rolling hopefully help u get medicare patient paid therapy maximum pocket go overall growth going multiyear processserge belanger needham company analyst thank youoperatorthe next question come brian abrams abraham excuse rbc capital marketsnevin varghese rbc capital market analyst hi everyone nevin brian congrats good quarter couple question sga strategic initiative maybe accelerate speak whether sale acceleration initiative planned drive increased uptake either yous ex yous well expansion geography ex yous fourth quarter guided toward increase sga million still case could expect patient service team place throughout year would something would add team seasonally well near end year maybe add team help reauth beginningjon stonehouse chief executive officer charlie maybe talk general build team anthony talk directly thingscharlie gayer chief commercial officer sure also talk specific initiative nevin asked investment made last year like said improve efficiency effectiveness would always looking make improvement margin see opportunity add little bit expect major add team point kind marginal addition particularly patient base grows patient service team grow slightly patient base grows seasonal growth kind longterm investment team always looking strengthen brand additional data additional initiative continue look opportunity like realworld evidence described prepared remarksanthony doyle chief financial officer term versus talked previously would expect increase sga year year broken kind fullyear impact increase charlies team partial impact last year ex yous side yeah smaller increase would think far term team focusing idea margin accretion investment making investment continue make going significantly le revenue generated get toward peak really excited start see margin accretion role getting u profitabilitynevin varghese rbc capital market analyst got thank wanted clarify mentioned increase yearoveryear sgaanthony doyle chief financial officer sorry sorry million millionnevin varghese rbc capital market analyst ok thank youanthony doyle chief financial officer yeahoperatorthe next question come liisa bayko evercore isi please go aheadliisa bayko evercore isi analyst hi congrats good quarter couple point clarification outside like ous revenue said include japanese royalty noanthony doyle chief financial officer yes include japanese royaltyliisa bayko evercore isi analyst ok gross net quarter maybe comment evolve course yearanthony doyle chief financial officer yes gross net reimbursed side yous closer historically guiding includes reauthorization impact copay assistance impact reset moving toward latter part year normalize closer range average u year liisa bayko evercore isi analyst ok revenue much japanese revenue much rapivab stuff could clarifyjon stonehouse chief executive officer revenue rapivabanthony doyle chief financial officer yeah million orladeyo million rapivab asking specific split product versus revenue generally give listen rapivab revenue part inconsequential especially orladeyo revenue getting point almost million quarterliisa bayko evercore isi analyst ok include japanese revenue line yescharlie gayer chief commercial officer million include japaneseanthony doyle chief financial officer million include orladeyo sorry japanese orladeyo revenue yesliisa bayko evercore isi analyst ok ok got inventory change quarteranthony doyle chief financial officer continue laserfocused ensuring significant quantity cost sale really really low team great job making sure enough territoriesliisa bayko evercore isi analyst ok great finally maybe talk pediatric expansion opportunity kind qualify term potential upsidecharlie gayer chief commercial officer sure think first point helen pointed huge need among kid oral therapy kid parent think highly anticipated product launch come market think yous kid may consideration prophylactic therapy evolving space prophy therapy available kid first oral change patient prophylaxis piece halo effect another way introduce orladeyo physician family patient expect important usjon stonehouse chief executive officer helen said remark enroll faster thought usually really good sign got something people want exactly happenedliisa bayko evercore isi analyst ok great thanksoperatorthe next question come stacy ku td cowen please go aheadstacy ku td cowen analyst hey thanks much taking question congratulation progress followup first regarding q outperformance think contributing new position growth characterize patient bit coming new prescribers versus current prescribers kind patient activation activity first question second around longterm expectation japanese launch orladeyo speak little bit seeing far early day feel comfortable kind long term opportunity last partnership team waiting full week result engaging discussion confirm would still getting result middle anticipate disclosing data streetcharlie gayer chief commercial officer stacy first question term color new growth similar seen getting prescription existing prescribers always adding new prescribers become aware orladeyo gain confidence mix patient also similar roughly switching prophy best tell naive prophylactic therapy consistent mentioned earlier consistent physician expect future see lot growth coming next year far japan think still fewer patient identified market could even hae patient team focused right driving use prophylaxis oral prophylaxis within diagnosed patient community building awareness orladeyo longer term think orladeyo manufacturer prophylaxis product patient diagnosis expect growing market next five year enthusiastic opportunity japanjon stonehouse chief executive officer stacy yeah expect data middle year matter since advancing seeking partner advance think data end day focus attentionstacy ku td cowen analyst ok understood thank muchoperatoroperator instruction next question come gena wang barclays please go aheadgena wang barclays analyst thank maybe one regarding japan since quite question japan market price also discount yous price relative like similar europe price second question regarding pediatric trial noticed singlearm study data could approvable based fda feedbackjon stonehouse chief executive officer charlie take japan price helen take charlie gayer chief commercial officer gena japanese price actually secondhighest price orladeyo price world moment course subject exchange rate variation moment close per year higher european pricesjon stonehouse chief executive officer helenhelen thackray chief research development officer question pediatric trial single arm fairly standard called extrapolation data point match exposure pediatric population exposure known effective adult population safety pk really submitted agencygena wang barclays analyst noticed also attack rate collection fda also consider data point like say threshold achievehelen thackray chief research development officer attack rate always collected following patient know patient well submitted part data set decision based safety exposuregena wang barclays analyst ok thank youoperatorthe next question come francois brisebois oppenheimer please go aheadfranc brisebois oppenheimer company analyst hi thanks term pediatric importance talked patient scenario would ever expect patient pediatric turn adult maybe change treatment option wondering remind u competition pediatric frontcharlie gayer chief commercial officer think would see patient kid need start prophylaxis oral going best option obvious reason lifelong disease think opportunity kid orladeyo long period time mentioned earlier family aspect genetic disease usually parent often sibling family member household opportunity whole family become aware benefit orladeyo would expect stay long termfranc brisebois oppenheimer company analyst understood thank youoperatorthe next question come jon wolleben jmp security please go aheadjon wolleben jmp security analyst hey thanks taking question one market research seemingly accurate past ask prescribing next month wondering actually ask longer term well ultimate usage factor growth projection also seems reflective uptake seeing ever expand asking asking get insight trajectory look like three four year linecharlie gayer chief commercial officer yeah thanks question jon absolutely look longer term ask longer term growth next month quarterly survey physician every quarter use information plus study year build much longerterm model also incorporate everything might come future ask physician opinion product think use go much larger market forecasting model predict future accurate first year launch every year team update model lot confidence future prediction billion peak revenue come come model incorporates forwardlooking market researchjon wolleben jmp security analyst year guy annual revamp guy let u know resultscharlie gayer chief commercial officer let know anything change year around middle year yeah goal accurate forecasting see anything different definitely let knowjon wolleben jmp security analyst got thanks charlieoperatoryour last question come chris raymond piper sandler please go aheadchris raymond piper sandler analyst thanks squeezing jon pretty open past folk asked guy strategic interest sort inbound interest think pretty clear lot buoyancy maybe lack better word orladeyos uptake guess discernible change term frequency maybe tenor inbound call guy strategicsjon stonehouse chief executive officer yeah chris mean know talk specific volume change answer willingness entertain remains unchanged public company shareholder interest mind someone interested take call change therechris raymond piper sandler analyst thank youoperatorthis concludes questionandanswer session would like turn conference back jon stonehouse closing remarksjon stonehouse chief executive officer yeah thanks interest company really really good start year super excited lead u term orladeyo trajectory advancing pipeline focused continuing momentum throughout year look forward updating new information great dayoperatoroperator signoff duration minutescall participantsjohn bluth senior vice president investor relation corporate communicationsjon stonehouse chief executive officercharlie gayer chief commercial officerhelen thackray chief research development officeranthony doyle chief financial officerunknown speakermaury raycroft jefferies analysttazeen ahmad bank america merrill lynch analystserge belanger needham company analystnevin varghese rbc capital market analystliisa bayko evercore isi analyststacy ku td cowen analystgena wang barclays analystfranc brisebois oppenheimer company analystjon wolleben jmp security analystchris raymond piper sandler analyst bcrx analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy